Replimune Stock Explodes as FDA Gives Skin Cancer Drug RP1 a Third Chance!
Replimune stock jumped after FDA gave RP1 melanoma drug another approval chance with fast review and resubmission.
NOTRELOAD AI
Tempus AI Gets FDA Green Light for Simpler Tumor-Only Cancer Test
Tempus AI gets FDA approval for tumor-only cancer DNA test, making diagnosis easier and boosting future revenue potential.
IFF to Sell Food Ingredients Unit to CVC – Keeps 10% Stake
IFF is selling its food ingredients unit to CVC for $4.3B to focus on core business and reduce debt, while staying partially invested.
Explosion at Blue Origin Leaves Amazon, AST SpaceMobile, and Space Stocks Reeling
Blue Origin’s New Glenn rocket burst into flames during a test, delaying Amazon’s satellite plans and AST SpaceMobile’s launch schedule. Space stocks drop sharply.
Agios Stops Tebapivat for LR-MDS – But It’s Still Moving Forward for Sickle Cell Disease
Agios scraps LR-MDS drug tebapivat after weak results but continues sickle cell trials; safety was good.
Record Quarter for NetApp: $1.95B Revenue Beat + Raised FY2027 Forecast
NetApp beat earnings, grew revenue, boosted cloud & AI products, and raised strong 2027 outlook above expectations.